Oncternal Therapeutics Announces Updated Safety And Efficacy Data For Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics announced updated safety and efficacy data for its Phase 1/2 study of ONCT-534, showing promising results for treating metastatic castration-resistant prostate cancer. The study included new dosing cohorts, with one patient showing significant PSA reduction and tumor shrinkage.
October 22, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncternal Therapeutics' updated Phase 1/2 study data for ONCT-534 shows promising results in treating metastatic castration-resistant prostate cancer, with significant PSA reduction and tumor shrinkage in some patients.
The updated data from the Phase 1/2 study of ONCT-534 indicates positive safety and efficacy results, which could boost investor confidence and potentially lead to a short-term increase in Oncternal's stock price. The promising results, including significant PSA reduction and tumor shrinkage, highlight the potential of ONCT-534 as a treatment for metastatic castration-resistant prostate cancer.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100